68Ga-HSA PET/CT Imaging for Protein-losing Enteropathy

Not yet recruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

May 31, 2026

Conditions
Cancer
Interventions
DRUG

68Ga-HSA

68Ga-HSA PET/CT: after intravenous injection of 2.22 MBq/kg body weight of quality-controlled 68Ga-HSA, a Siemens Biograph PET/CT scan will be applied within 1 h, and the scan range will be from the top of the head to 1/3 of the upper thigh.

Trial Locations (1)

100142

Beijing Cancer Hospital, Beijing

All Listed Sponsors
collaborator

Suzhou Transcenta Therapeutics Co., Ltd.

INDUSTRY

lead

Peking University Cancer Hospital & Institute

OTHER